Eton Pharmaceuticals Inc (ETON)
3.65
+0.15
(+4.29%)
USD |
NASDAQ |
May 01, 16:00
3.67
+0.02
(+0.55%)
After-Hours: 20:00
Eton Pharmaceuticals Research and Development Expense (Quarterly): 1.047M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.047M |
September 30, 2023 | 0.615M |
June 30, 2023 | 1.125M |
March 31, 2023 | 0.535M |
December 31, 2022 | 0.944M |
September 30, 2022 | 0.744M |
June 30, 2022 | 0.69M |
March 31, 2022 | 1.618M |
December 31, 2021 | 0.681M |
September 30, 2021 | 2.678M |
June 30, 2021 | 1.99M |
March 31, 2021 | 0.886M |
December 31, 2020 | 3.401M |
Date | Value |
---|---|
September 30, 2020 | 2.826M |
June 30, 2020 | 1.609M |
March 31, 2020 | 6.268M |
December 31, 2019 | 0.233M |
September 30, 2019 | 3.418M |
June 30, 2019 | 1.439M |
March 31, 2019 | 6.465M |
December 31, 2018 | 1.102M |
September 30, 2018 | 1.544M |
June 30, 2018 | 1.707M |
March 31, 2018 | 1.274M |
September 30, 2017 | 1.564M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.233M
Minimum
Dec 2019
6.268M
Maximum
Mar 2020
1.724M
Average
1.125M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
Evoke Pharma Inc | 0.0226M |
Outlook Therapeutics Inc | 4.529M |
NovaBay Pharmaceuticals Inc | 0.004M |
Palatin Technologies Inc | 5.554M |
iBio Inc | 1.535M |